Our Financial Highlights for 2018
2018 delivered continued strong performance from our International Star brands, led by KELO-COTE™.
For the first time, our overseas sales exceeded those from the UK market.
Nizoral acquired from Johnson & Johnson for the Asia Pacific region in June 2018 for £60m; revenues in line with expectations and integration progressing well.
Vamousse integration completed and Alliance subsidiary fully established in the US; Vamousse revenues up 16% year on year under Alliance management.
To view in detail click here to download our 2018 Annual Report.
Please view our five year financial summary below
|Year ended 31 December 2014 £m||Year ended 31 December 2015 £m||Year ended 31 December 2016 £m||Year ended 31 December 2017 £m restated||Year ended 31 December 2018 £m|
|Operating profit before non-underlying items||11.8||10.6||25.6||25.8||28.9|
|Non-underlying operating items||0.6||(6.3)||-||4.4||(5.3)|
|Profit before tax before non-underlying items||10.8||11.0||22.2||23.9||28.1|
|Profit before tax after non-underlying items||10.2||15.2||22.2||28.3||22.8|
|Average shares in issue (millions)||264.1||272.7||469.4||473.8||497.2|
|Shares in issue at period end (millions)||264.1||468.2||472.6||475.0||518.2|
|Earnings per share – basic (p)||3.17||4.65||3.85||6.08||3.69|
|Earnings per share – adjusted underlying basic (p)||3.36||3.69||3.69||4.05||4.54|
* Non-IFRS alternative performance measures (see note 34). See-through revenue includes sales from Nizoral as if they had been invoiced by Alliance. For statutory accounting purposes the product margin on Nizoral sales is included within Revenue, in line with IFRS 15
** 2017 comparatives restated following the adoption of IFRS 15 Revenue from Contracts with Customers and IFRS 16 Leases